Investors Urged to Join Class Action Against Mereo BioPharma for Alleged Securities Fraud

Investor Alert: Class Action Against Mereo BioPharma

On March 19, 2026, Pomerantz LLP, a respected law firm specializing in class action lawsuits, declared the initiation of a class action against Mereo BioPharma Group plc, trading under the ticker MREO on NASDAQ. This legal action is directed at investors who incurred losses on their investments in Mereo, inviting them to consider joining the lawsuit. The firm has notably encouraged affected investors to reach out to their legal team for further information.

Background on Mereo BioPharma

Mereo BioPharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases and specialty conditions. While the company aimed to address significant unmet medical needs, it faced challenges that led to significant stock price fluctuations, indicating potential misrepresentations and mismanagement.

Allegations of Fraud

The class action centers on claims that Mereo, along with certain officers and directors, may have engaged in securities fraud or other unlawful business practices. This speculation arose sharply during 2025, particularly following two critical updates involving clinical trials for their products. On July 9, 2025, Mereo, in conjunction with its partner Ultragenyx Pharmaceutical Inc., announced significant progress concerning the Phase 3 Orbit study regarding UX143 (setrusumab) in patients affected by osteogenesis imperfecta.

The excitement led to a sharp increase in trading volume; however, subsequent disclosures birthed skepticism. Mereo's ADR price dropped dramatically, falling by $1.25 per share, translating to a staggering 42.52% decline, the following day after the announcement.

Further compounding investor concerns, on December 29, 2025, the company reported dismal outcomes from the Orbit and Cosmic Phase 3 studies, indicating that the efficacy endpoints had not been met. This statement precipitated an extraordinary drop in the ADR price, which plummeted by $2.02 per ADR, or a staggering 87.7%, closing at just $0.29 per ADR by the end of the trading period.

Join the Lawsuit

Affected investors are advised to take action promptly, as the deadline for appointing a Lead Plaintiff in the class action is April 6, 2026. Interested parties can obtain a copy of the Complaint and find additional instructions on how to join this class action by visiting the Pomerantz LLP website. Those inquiring are encouraged to provide their details, including mailing address, phone number, and the number of shares purchased, to facilitate the process.

Pomerantz LLP has a long-standing reputation in advocating for investors, embodying a commitment to securing justice for those impacted by corporate malfeasance. Founded by the renowned Abraham L. Pomerantz, the firm has been a pioneer in the field of securities class actions, having successfully recovered millions in damages for victims of fraud.

Conclusion

As the investors grapple with the ramifications of Mereo BioPharma's developments, the call for action by Pomerantz LLP serves as a reminder of the legal recourse available for those who believe they have been misled. With impacts on share values and investor trust, the unfolding legal landscape will be crucial for affected parties and may set a precedent for future securities litigation.

For more guidance or questions regarding the class action, you can contact Danielle Peyton at Pomerantz LLP at [email protected] or by phone at 646-581-9980, or toll-free at 888.4-POMLAW, Ext. 7980.